产品说明书
Pioglitazone HCl
 |
同义名 : | 匹格列酮盐酸盐 ;AD 4833;U 72107A;Pioglitazone (hydrochloride);U-72107E;Pioglitazone hydrochloride |
| CAS号 : | 112529-15-4 | |
| 货号 : | A426266 | |
| 分子式 : | C19H21ClN2O3S | |
| 纯度 : | 99% | |
| 分子量 : | 392.9 | |
| MDL号 : | MFCD04975446 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(267.24 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Pioglitazone completely eliminates beta cell necrosis induced by AGEs when added to the AGEs culture medium. Additionally, Pioglitazone fully inhibits any increase in caspase-3 activation caused by AGEs, thus returning caspase-3 activity to levels observed in control cells. As anticipated, AG effectively counteracts the viability impairment induced by AGEs[2]. | ||
| 细胞研究 | |||||
|---|---|---|---|---|---|
| 细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
| COS cells | Function assay | Transcriptional activation in COS cells expressing PPAR gamma and RXR alpha; values in the parentheses indicates 95% confidence interval, EC50=0.49 μM | 11906293 | ||
| HepG2 cells | Function assay | Peroxisome proliferator activated receptor gamma agonistic activity in HepG2 cells, EC50=7.6 μM | 10714503 | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00770575 | Cardiovascular Diseases | Phase 2 | Completed | - | - |
| NCT00521820 | Diabetes Mellitus | Phase 3 | Terminated(Higher incidence of... 展开 >> hospitalization for congestive heart failure in pioglitazone-treated subjects compared to glyburide treated subjects.) 收起 << | - | - |
| NCT01225081 | Type 2 Diabetes Mellitus | Phase 3 | Completed | - | Japan ... 展开 >> Chubu, Japan Chugoku, Japan Hokkaido, Japan Kansai, Japan Kantou, Japan Kyushu, Japan Touhoku, Japan 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.55mL 0.51mL 0.25mL |
12.73mL 2.55mL 1.27mL |
25.45mL 5.09mL 2.55mL |
| 参考文献 |
|---|